Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. By demonstrating a significant reduction in the relative risk of a renal-specific composite endpoint, Invokana became the first antidiabetic drug to demonstrate a renoprotective effect in a dedicated renal outcomes trial. The SGLT-2 inhibitor has opened the door for this drug class to be used to lower eGFR limits, potentially shifting treatment patterns in this market. Bayer’s Kerendia is the first and only mineralocorticoid receptor antagonist approved by the FDA to slow the progression of DN. This report provides important insight into how these agents are used in the management of DN and how practices are evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DN patients?
- How have SGLT-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of DN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DN patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key companies: Boehringer Ingelheim, AstraZeneca, Bayer, Johnson & Johnson, Novo Nordisk, Eli Lilly
Key drugs: Invokana, Jardiance, Farxiga, Kerendia
KEY FEATURE
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
